Comparative Pharmacology
Head-to-head clinical analysis: ISOETHARINE HYDROCHLORIDE S F versus ISOETHARINE MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOETHARINE HYDROCHLORIDE S F versus ISOETHARINE MESYLATE.
ISOETHARINE HYDROCHLORIDE S/F vs ISOETHARINE MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
Selective beta-2 adrenergic receptor agonist; stimulates adenylate cyclase, increasing cAMP in bronchial smooth muscle, leading to bronchodilation.
Inhalation: 1-2 inhalations of a 340 mcg/metered dose every 4 hours as needed. Nebulization: 500 mcg (0.5 mL of a 0.1% solution) every 4 hours as needed.
Inhalation: 1-2 inhalations (0.34 mg per actuation) via metered-dose inhaler every 4-6 hours as needed; or 0.25-0.5 mL of 1% solution diluted in 2-3 mL of normal saline via nebulizer every 4-6 hours.
None Documented
None Documented
2-4 hours; clinical context: short half-life supports continuous or repeated dosing for acute bronchospasm.
Terminal elimination half-life is approximately 2.5–5 hours in adults after inhalation; may be prolonged in patients with hepatic or renal impairment.
Primarily renal excretion of unchanged drug and metabolites; 60-70% excreted in urine as unchanged drug and sulfate conjugates, with less than 10% eliminated in feces via biliary excretion.
Primarily renal excretion of unchanged drug and metabolites (sulfate and glucuronide conjugates); approximately 40-50% excreted renally as unchanged drug within 24 hours, with the remainder as metabolites. Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist